Please assess the completion status of the following clinical trial:

Trial Title: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologic evidence of NASH upon central read of a liver biopsy obtained no more than 6 months before Day 1 defined by presence of all 3 key histological features of NASH according to NASH CRN criteria.~2. Histologic evidence of fibrosis stage 2 or stage 3 as defined by the NASH CRN scoring of fibrosis, or~   Histologic evidence of fibrosis stage 1a or stage 1b if accompanied by ≥1 of the following risk factors:~  * Obesity (BMI ≥30 kg/m2)~  * Type 2 diabetes diagnosed per 2013 American Diabetes Association criteria~  * ALT \>1.5× upper limit of normal (ULN).~3. For subjects with a historical biopsy, is either not taking or is on stable doses of TZDs/glitazones or vitamin E for 6 months before Day 1.~4. Stable body weight.~Exclusion Criteria:~1. Model for End-stage Liver Disease (MELD) score \>12~2. ALT ≥10× ULN~3. HbA1c \>9.5%~4. Total bilirubin \>1.5 mg/dL~5. Evidence of other known forms of known chronic liver disease such as alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)~6. History of liver transplant, or current placement on a liver transplant list~7. Current or history of significant alcohol consumption~8. Prior or planned ileal resection, or prior or planned bariatric surgery~9. Histological presence of cirrhosis~10. History of biliary diversion~11. Known positivity for human immunodeficiency virus infection.~12. Acute cholecystitis or acute biliary obstruction.~13. BMI \>45 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 10 mg Obeticholic Acid (Type: EXPERIMENTAL): 10 mg Obeticholic Acid daily for the remainder of the study
- 25 mg Obeticholic Acid (Type: EXPERIMENTAL): 25 mg Obeticholic Acid daily for the remainder of the study
- Placebo (Type: PLACEBO_COMPARATOR): One tablet daily for the remainder of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).